Skip to Main Content

Paper Details

Validation of Serum Biomarkers That Complement CA19-9 in Detecting Early Pancreatic Cancer Using Electrochemiluminescent-Based Multiplex Immunoassays.
Biomedicines
6
2021
CA-125, CA19-9, CEA, HE4, IPMN, PDAC, Pancreatic Cancer, Pancreatic ductal adenocarcinoma, benign pancreatic conditions, chronic pancreatitis, intraductal papillary mucinous neoplasm, malignancy, pancreatic cancer, patients
Author NameAffiliation
Lori J SokollCenter for Biomarker Discovery and Translation, Johns Hopkins University School of Medicine
Lori J SokollThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Daniel W ChanCenter for Biomarker Discovery and Translation, Johns Hopkins University School of Medicine
Daniel W ChanThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Daniel W ChanCenter for Biomarker Discovery and Translation, Johns Hopkins University School of Medicine
Daniel W ChanThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Zhen ZhangCenter for Biomarker Discovery and Translation, Johns Hopkins University School of Medicine
Zhen ZhangThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
  • 1 - 8

Datasets

Release 1.2